Interventional, randomised, double-blind, sequential-group, placebo-controlled single ascending dose study investigating the safety, tolerability, and pharmacokinetic properties of Lu AF34134 in healthy young men and healthy elderly men and women, and open-label, three-period crossover, food interaction study of Lu AF34134 in healthy elderly men and women.

The research medication is a new medication developed for the treatment of
Parkinson*s disease.

- to examine the safety and tolerability of the research medication
- to examine how the research medication is absorbed, broken down and excreted
by the body.

This is a randomised, double-blind, placebo-controlled single ascending dose
study.

The study will start with a screening. At the screening a physical examination
will take place and a few other standard
medical assessments will be performed (ECG, vital signs). Furthermore a blood
and urine sample will be taken for
laboratory tests and an alcohol breath test and drug screen will be done.

During the stay in the clinic the subject will receive the study medication and
on several time points blood will be taken
and urine will be collected. The subjects will be asked for possible side
effects on regular basis. Furthermore several
safety assessments will be done frequently.

Finally, a follow-up visit will take place.

The study medication has not been previously tested in humans. However,
pharmacological compounds with similar mode of action have been tested in human
clinical trials, but are not yet registered by authorities for use in patients.
The results, seen in literature, obtained from these tested compounds indicated
that such compounds are generally well tolerated and some side effects have
been reported. These most common adverse effects in patients with Parkinson*s
disease appear to be nausea, aggravation of dyskinesia, dizziness and insomnia.

The doses decided to be administered in this study have been decided based on
data from preclinical studies in animals. The risks with these doses are
considered to be minimal, but as with drugs, unforeseeable side effects could
occur. In order to minimize the risks, the health will be monitored carefully
during the whole study.